Compare TVRD & POM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TVRD | POM |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.3M | 38.8M |
| IPO Year | N/A | 2025 |
| Metric | TVRD | POM |
|---|---|---|
| Price | $3.94 | $0.33 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $51.67 | N/A |
| AVG Volume (30 Days) | 135.5K | ★ 4.7M |
| Earning Date | 02-21-2026 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $51,210,721.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.13 |
| 52 Week Low | $3.74 | $0.26 |
| 52 Week High | $43.65 | $6.43 |
| Indicator | TVRD | POM |
|---|---|---|
| Relative Strength Index (RSI) | 34.78 | N/A |
| Support Level | $3.90 | N/A |
| Resistance Level | $4.46 | N/A |
| Average True Range (ATR) | 0.24 | 0.00 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 14.29 | 0.00 |
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.